PAH drug trial halted early, leaving questions unanswered

NCT ID NCT05764265

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study aimed to gather more information about the long-term safety and effectiveness of the experimental drug LTP001 for people with pulmonary arterial hypertension (PAH), a serious lung and heart condition. It was designed as a follow-up for 31 people who had completed an earlier trial, allowing them to receive LTP001 for up to a year. However, the study was terminated early, so the planned long-term data on how well the drug works was not collected.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Caba, Buenos Aires, C1025ABI, Argentina
Novartis Investigative Site

Dresden, Saxony, 01307, Germany
Novartis Investigative Site

Heidelberg, 69120, Germany
Novartis Investigative Site

Amsterdam, North Holland, 1081 HV, Netherlands
Novartis Investigative Site

Krakow, 31 202, Poland
Novartis Investigative Site

Lodz, 91-347, Poland
Novartis Investigative Site

Wroclaw, 50-556, Poland
Novartis Investigative Site

Barcelona, 08036, Spain
Novartis Investigative Site

Madrid, 28041, Spain
Novartis Investigative Site

Málaga, 29010, Spain
Novartis Investigative Site

Sheffield, South Yorkshire, S10 2JF, United Kingdom
Pulmonary Associates PA

Mesa, Arizona, 85206, United States

Conditions

Explore the condition pages connected to this study.

PULMONARY ARTERIAL HYPERTENSION